Abstract:Cocrystallization of racemic-compound-forming chiral molecules can result in conglomerate cocrystals or diastereomerically related cocrystals, which enable the application of chiral separation techniques such as preferential crystallization and classic resolution. Here, a systematic method to identify the types and phase diagrams of cocrystals formed by chiral target compounds and candidate coformers in a particular solvent system is presented, which allows the design of suitable chiral resolution processes. The method is based on saturation temperature measurements of specific solution compositions containing both enantiomers of chiral molecules and a coformer. This method is applied to analyze three different systems. For racemic phenylalanine (Phe) in water/ethanol mixtures one of the enantiomers selectively cocrystallizes with the opposite enantiomer of valine (Val), forming the more stable diastereomerically related cocrystal. The racemic compound ibuprofen crystallizes with the nonchiral coformer 1,2-bis(4-pyridyl)ethane (BPN) as racemic compound cocrystals. More interestingly, when it is combined with <i>trans</i>-1-(2-pyridyl)-2-(4-pyridyl)ethylene (BPE), the racemic compound ibuprofen cocrystallizes as a conglomerate, which in principle enables the application of preferential crystallization of this racemic compound. The systematic method shows the benefit of using pseudo-binary phase diagrams. Such pseudo-binary phase diagrams depict the saturation temperature on a very specific route through the quaternary phase diagram, allowing the identification of various cocrystal types as well as the corresponding cocrystallization conditions. The systematic method can be used to identify a suitable solid phase for chiral separation, and the obtained phase diagram information enables the performance of a crystallization-mediated chiral resolution process design. Such a guideline for a chiral resolution process design has never been reported for conglomerate cocrystal systems such as IBU:BPE, presented in this study.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.cgd.0c00890?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.cgd.0c00890</a>.XRPD diffractograms of all relevant crystalline products from the present study (<a class="ext-link" href="/doi/suppl/10.1021/acs.cgd.0c00890/suppl_file/cg0c00890_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Shortcut Method for Solubility Prediction and Preferred Stability of Diastereomeric Cocrystals

Cocrystal Solubility Advantage and Dose/Solubility Ratio Diagrams: A Mechanistic Approach To Selecting Additives and Controlling Dissolution-Supersaturation-Precipitation Behavior

Screening Approach for Identifying Cocrystal Types and Resolution Opportunities in Complex Chiral Multicomponent Systems

Bioavailability-Enhancing Cocrystals: Screening, In Vivo Predictive Dissolution, and Supersaturation Maintenance

The construction, prediction and measurement of co-crystal ternary phase diagrams as a tool for solvent selection

Computational screening for prediction of co-crystals: method comparison and experimental validation

Pharmaceutical Cocrystals: A Novel Systematic Approach for the Administration of Existing Drugs in New Crystalline Form

Thermodynamic and Molecular Recognition Mechanism of Diastereomeric Salt/Cocrystal-Induced Chiral Separation

Conformation, Virtual Cocrystal Screening, Synthesis and Determination of Dipyridamole

Evaluation on Cocrystal Screening Methods and Synthesis of Multicomponent Crystals: A Case Study

Solvent Effect on Molecular Conformational Evolution and Polymorphic Manipulation of Cimetidine

Solubility Behavior and Solution Chemistry of Indomethacin Cocrystals in Organic Solvents

Cocrystal: A Review on the Design and Preparation of Pharmaceutical Cocrystals

Modeling the solubility of pharmaceuticals in pure solvents and solvent mixtures for drug process design

Selective solvent inclusion as a tool for mapping molecular properties in crystal structures: a diethylstilbestrol example

Solution Stability of Pharmaceutical Cocrystals

Advances in solvent based cocrystallization: Bridging the gap between theory and practice

Crystallization solvent design based on a new quantitative prediction model of crystal morphology

Role of Coformers in Solubility Enhancement of Poorly Soluble Drugs through Cocrystallization: An Overview

Optimisation of Pharmaceutical Cocrystal Dissolution Performance through a Synergistic Precipitation Inhibition

Effect of functional group position in co-formers and solvent on cocrystal polymorphism/stoichiomorphism: a case study